Ares Trading S.a.

Zymogenetics, Inc.

Mayo Foundation for Medical Education and Research

Herve Broly

Martin Jordan

Matthieu Stettler

David Bruhlmann

Eric Sievers

Sharon J Busby

Arnaud Ythier

Ivan Nestorov

Anais Muhr

Jane A Gross

Stephen M Ansell

Jan Öhrström

Rafael A Ponce, Jr

Hans Otto Lennart Graffner

Yolande Rouiller

Gabrielle Leclercq

Arnaud Perilleux

Jonathan Souquet

Sergio Peano

Jennifer Visich

The present invention relates to methods and compositions for modulating glycosylation profile, such as the galactosylation profile, of recombinant proteins expressed by mammalian host cells during the cell culture process by supplementing cell culture media with a peracetyl galactose.

Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose

The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of a triazine dye or supplemented with an effective amount of a triazine dye, whereby production of said protein is increased relative to cells grown without said triazine dye or any other inducer.

Methods for modulating production profiles of recombinant proteins

The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of 4,4'diisothiocyanostilbene-2,2&#x2032;-disulfonic acid (DIDS) or supplemented with an effective amount of DIDS, whereby production of said protein is increased relative to cells grown without DIDS.

The present invention relates to new serum- and protein-free culture media. These media are high performance culture media, which notably improve mammalian fed-batch cultures. The present invention also relates to methods for preparing and/or designing the medium, and methods of use thereof.

Medium for high performance mammalian fed-batch cultures

The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF&#x2014;R-Fc-fusion protein comprising the extracellular domain of BAFF&#x2014;R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN&#xae;, (rituximab),ocrelizumab, ofatumumab (HuMax-CD20&#xae;), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.

Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease

The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenstr&#xf6;m's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules

In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.

Methods for treating autoimmune diseases using a TACI-Ig fusion molecule

The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Growing community of inventors

Chatel-St-Denis, Switzerland

Herve Broly